Topic: clinical trials

The congress connects experimental and clinical pharmacology, from identifying therapeutic targets and testing mechanisms in preclinical models to clinical trials, access to treatment and evidence from routine care. Its programme examines synaptic and cellular communication in neurodegeneration, immunometabolism, inflammation, oncology, precision medicine and sex-aware experimental design. Sessions also address drug development, regulatory decisions, artificial intelligence and the sustainability of pharmacological research. Plenary lectures connect unmet needs in oncology to improved care and

This round opened on 30 September 2026. Four streams support pilot feasibility studies for rare cancers, rare diseases or unmet need; clinical trials addressing those conditions; trials filling evidence gaps relevant to Australian health technology assessment; and prevention trials reducing disease risk, onset or progression. The aim is to strengthen clinical evidence and access to effective care for Australians. New applicants must submit minimum data by 5:00 pm ACT local time on 2027-03-10; this earlier mandatory milestone is the listing deadline. Complete applications close at 5:00 pm ACT l

Funding for clinical trials and prospective or retrospective cohort studies, of either large or small scale, addressing important gaps in knowledge and producing evidence relevant to health outcomes, practice or policy. New applicants must submit minimum data by 5:00 pm ACT local time on 2026-10-07; this earlier mandatory milestone is the listing deadline. Complete applications close at 5:00 pm ACT local time on 2026-11-04. Apply through the eligible administering organisation using Sapphire. Full guidelines require GrantConnect login. Trial or cohort research for up to five years; excludes in

Fully funded doctoral studentship in the Ali Lab at the Cancer Research UK Cambridge Institute, starting in October 2027. The project combines spatial multiomics with deep learning to identify treatment-response biomarkers in breast cancer. It will analyse large multimodal datasets from observational cohorts and clinical trials, using representation and cross-modal learning to study target expression, tissue architecture and tumour heterogeneity. Training spans quantitative pathology, multiplexed imaging and predictive modelling.

NIH PA-25-304 supports exploratory biomedical, behavioral and clinical research at an early conceptual stage, including risky approaches, new methods and models. Clinical trials are not permitted. Projects must fit a participating NIH institute or center. The next new-application deadline is October 16, 2026 at 5 p.m. in the applicant organization’s local time; the next resubmission deadline is November 16. Direct costs are limited to USD 275,000 over two years and USD 200,000 in any one year. Apply through ASSIST, Grants.gov Workspace or an institutional system; organizational registrations a

Analyse clinical trials and linked register data on stress-related ill health and persistent fatigue, including treatment prediction, mediation, moderation and long-term outcomes. Work covers healthcare use, sickness absence, medication and socioeconomic measures. The role belongs to Karolinska’s Division of Psychology and is mainly based at Gustavsberg University Primary Healthcare Centre. This is a full-time temporary appointment with an intended start during autumn 2026. Apply online by 1 October 2026.

PA-25-301, posted December 18, 2024. NIH's parent announcement for investigator-initiated R01 research project grants not proposing clinical trials; standard NIH submission policies and due dates apply, with the listing closing January 7, 2028.

This talk will examine how approaches such as ‘big data’ and new ways of delivering clinical trials can improve current services for older people with mental illness (jam today) and identify and deliver new treatments in the future (jam tomorrow).

Visual restoration is certainly the greatest challenge for brain-machine interfaces with the high pixel number and high refreshing rate. In the recent year, we brought retinal prostheses and optogenetic therapy up to successful clinical trials. Concerning visual restoration at the cortical level, prostheses have shown efficacy for limited periods of time and limited pixel numbers. We are investigating the potential of sonogenetics to develop a non-contact brain machine interface allowing long-lasting activation of the visual cortex. The presentation will introduce our genetic-based brain machi

Dementia with Lewy bodies (DLB) is a synucleinopathy but more than half of patients with DLB also have varying degrees of tau and amyloid-β co-pathology. Identifying and tracking the pathologic heterogeneity of DLB with multi-modal biomarkers is critical for the design of clinical trials that target each pathology early in the disease at a time when prevention or delaying the transition to dementia is possible. Furthermore, longitudinal evaluation of multi-modal biomarkers contributes to our understanding of the type and extent of the pathologic progression and serves to characterize the temp

On April 22, 2021, Dr. Alan J Thompson of the University College London and the UCL Institute of Neurology, London, UK will deliver the Hughlings Jackson Lecture entitled, “Making Progress in Progressive MS – the Ultimate Challenge!” Established in 1935, the Hughlings Jackson Lecture is The Neuro’s premier scientific lecture. It honors the legacy of British neurologist John Hughlings Jackson (1835-1911) who pioneered the development of neurology as a medical specialty. Talk Abstract : The international focus on progressive MS, driven by the Progressive MS Alliance amongst others, together w

One of the major challenges in developing therapeutics for the neurodegenerative disorders is the blood-brain barrier, limiting the availability of systemically administered therapies such as recombinant proteins or monoclonal antibodies from reaching the brain. Direct central nervous system (CNS) gene therapy using adeno-associated virus vectors expressing a therapeutic protein, monoclonal antibody or inhibiting RNA-coding sequences has two characteristics ideal for therapy of neurodegenerative disorders: circumventing the blood-brain barrier by directly expressing the therapy in the brain an

This webinar is mainly focused on “Biomarkers for Addiction Treatment Development: fMRI Drug Cue Reactivity as an Example”. Biomarkers and Biotypes of Drug Addiction: funding opportunities at NIDA, Tanya Ramey (NIDA, US) Neuroimaging-based Biomarker Development for Clinical Trials, Owen Carmicheal (Pennington Biomedical Research Center, USA) ENIGMA-Addiction Cue Reactivity Initiative (ACRI) and Checklist, Hamed Ekhtiari (Laureate Institute for Brain Research, USA) ENIGMA-ACRI Checklist: Participant Characteristics, General fMRI Information, General Task Information, Cue Information, Task-r